Earnings call transcript: Johnson & Johnson Q1 2026 earnings beat expectations

Johnson & Johnson beat Q1 2026 expectations with revenue of $24.1B versus $23.61B consensus and adjusted EPS of $2.70 versus $2.68, while also raising full-year guidance. Operational sales grew 6.4%, but Stelara sales fell 61.7% on biosimilar competition, offset by strong growth in DARZALEX, Tremfya, and MedTech franchises. Shares were down 0.5% premarket despite the beat, reflecting investor focus on mix pressure, tariffs, and competitive headwinds.

Analysis

The market is treating this as a clean defensive-quality print, but the more important read-through is that JNJ is proving it can replace a multi-billion dollar patent cliff with a cascade of smaller launches across three franchises. That lowers single-asset risk and, more importantly, compresses the earnings volatility that usually keeps healthcare multiples muted. The immediate second-order winner is the rest of large-cap pharma with credible launch books; the losers are companies still hostage to one or two aging blockbusters, because the bar for capital deployment into those names just rose.

The Stelara reset matters less as a top-line drag than as a portfolio transition signal: management is effectively telling investors to underwrite a temporary mix hit now in exchange for a cleaner growth profile later. The key mechanism is that new launches are already offsetting the decline, so the earnings conversation shifts from “how big is the hole?” to “how fast do the replacements scale?” That should support multiple expansion if launch execution stays intact, but it also means the stock becomes more sensitive to any sign of payer friction or slower reimbursement, especially around newly launched high-touch products.

The hidden catalyst is not the quarter itself but the setup into the back half: U.S. reimbursement milestones, regulatory readouts, and first-year utilization curves for several launches will stack into a much easier comparison base. If those products take share as quickly as management implies, consensus 2027–2028 numbers are still too low; if they don’t, the market will punish the stock because the current valuation already gives credit for durable acceleration. My view is the downside is more tactical than structural, with the real risk being that launch momentum decelerates before the portfolio offset becomes broad enough.

Contrarian angle: the street is likely underestimating how much of JNJ’s future EPS torque comes from operational leverage rather than revenue growth alone. With the mix shift away from mature products and the eventual normalization of some cost items, even mid-single-digit sales growth can translate into high-single-digit EPS growth, which makes the dividend and defensive narrative more powerful in a risk-off tape. In other words, this is less a pure “safe haven” trade and more a gradual re-rating story if execution remains clean for the next 2-3 quarters.

Key Decisions for Investors

• Long JNJ into the next 1-2 quarters on pullbacks below the post-earnings level; target 6-10% upside if launch momentum and guidance credibility hold, with stop-loss on any evidence of reimbursement slippage or slowing new-patient adds.
• Pair trade: long JNJ / short a basket of single-product healthcare names over the next 3-6 months. The thesis is lower idiosyncratic cliff risk and better earnings durability; the pair should outperform if the market keeps rewarding portfolio breadth.
• Buy JNJ call spreads 3-6 months out, struck slightly out of the money, to capture multiple expansion from launch-driven consensus revisions while capping premium if the stock stays range-bound.
• Add to dividend/defensive healthcare exposure via JNJ versus cyclicals in a risk-off regime. The combination of raised guidance and capital return makes it one of the cleaner large-cap hedge assets if geopolitics keep volatility elevated.
• Watch for a catalyst trade around the next quarterly read on icotrokinra and INLEXZO utilization; if early uptake stays steep, add on confirmation rather than chase, since the stock can re-rate in steps rather than linearly.